iTeos Therapeutics ( (ITOS) ) has provided an update.
iTeos Therapeutics has revealed promising interim results from the Phase 2 GALAXIES Lung-201 study, demonstrating significant improvements in treating advanced PD-L1 high non-small cell lung cancer with the combination of belrestotug and dostarlimab. This treatment showed a meaningful objective response rate, outperforming dostarlimab monotherapy, and has a safety profile consistent with existing checkpoint inhibitor combinations. The data supports the ongoing Phase 3 trial and will be further discussed in an upcoming conference call hosted by the company.
For an in-depth examination of ITOS stock, go to TipRanks’ Stock Analysis page.
